
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450
If Undeliverable Return in Ten Days

OFFICIAL BUSINESS PENALTY FOR PRIVATE USE, \$300

AN EQUAL OPPORTUNITY EMPLOYER



United States Patent and Trademark Office UNITED STATES DEPARTMENT OF COMMERCE. United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov NOV 1 8 2008 FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. ILING DATE 10/792,291 03/02/2004 James H. Coombs NAGACO.074A 3167 10/27/2008 **EXAMINER** Donald Bollella YU, MELANIE J **DB** Technical Consulting 126 Almador ART UNIT PAPER NUMBER Irvine, CA 92614 1641

Please find below and/or attached an Office communication concerning this application or proceeding.

DELIVERY MODE

**PAPER** 

10/27/2008

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Summary	10/792,291	COOMBS ET AL.				
Onice Action Summary	Examiner	Art Unit				
The MAILING DATE of this communication app	MELANIE YU	1641				
Period for Reply	cars on the cover sneet with the c	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).						
Status						
1) Responsive to communication(s) filed on 25 Ju	<u>ıly 2008</u> .					
2a) This action is <b>FINAL</b> . 2b) ⊠ This	action is non-final.					
3) Since this application is in condition for allowar	·					
closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.				
Disposition of Claims		*				
4)⊠ Claim(s) <u>1-66</u> is/are pending in the application.						
4a) Of the above claim(s) <u>1-14 and 22-54</u> is/are	withdrawn from consideration.	·				
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>15-21 and 55-66</u> is/are rejected.	•					
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/o	r election requirement					
are subject to restriction and/or	election requirement.					
Application Papers	•					
9)☐ The specification is objected to by the Examine	r.					
10)⊠ The drawing(s) filed on <u>02 March 2004</u> is/are: a	a)⊠ accepted or b)☐ objected t	to by the Examiner.				
Applicant may not request that any objection to the						
Replacement drawing sheet(s) including the correcti  11) The oath or declaration is objected to by the Ex						
Trip The bath or declaration is objected to by the Ex	aminer. Note the attached Office	e Action of form PTO-152.				
Priority under 35 U.S.C. § 119						
12)☐ Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119(a	n)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents						
2. Certified copies of the priority documents	•					
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.						
222 202 2020000 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2020 2						
		•				
·						
Attachment(s)	A) [] 1-4	· (DTO 442)				
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summary Paper No(s)/Mail D					
3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date 7/15, 8/3, 1/8.	5) Notice of Informal F . 6) Other:	Patent Application				

## **DETAILED ACTION**

## Election/Restrictions

1. Applicant's election without traverse of Group IV, claims 15-21, in the reply filed on 25 July 2008 is acknowledged. New claims 55-66 also read on this group and are examined on the merits.

Claims 1-14 and 22-54 have been withdrawn.

## Claim Objections

2. Claim 66 is objected to because of the following informalities: the claim contains duplicate punctuation at the end of the claim. Only one "." should be present.

Appropriate correction is required.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

- (b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.
- 3. Claim 15 is rejected under 35 U.S.C. 102(b) as being anticipated by Sheppard, Jr. et al. (US 6,143,247).

Sheppard, Jr. et al. teach an optical bio-disc comprising: a substantially circular substrate having a center and an outer edge (col. 10, lines 21-25); an active layer associated with the substrate (detection chamber has porous filter, col. 15, lines 8-11); a target zone disposed between the center and the outer edge (detection chamber is on platform, and is therefore between center and outer edge, col. 10, lines 32-34); and a

plurality of capture antibodies bound to the active layer such that the antibodies are immobilized on the active layer in the target zone (detection chamber coated with specific binding reagent, col. 6, lines 13-21; specific binding reagent may be antibodies, col. 10, lines 32-42; specific binding reagents are immobilized on the porous filter, col. 15, lines 5-11).

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- Considering objective evidence present in the application indicating obviousness or nonobviousness.
- 4. Claims 16-20 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sheppard, Jr. et al. (US 6,143,247) in view of Tachikawa et al. (US 2002/0187510).

Sheppard, Jr. et al. teach an active layer that is a filter associated with the substrate in the detection chamber, but fail to teach the porous filter material being nitrocellulose.

Application/Control Number: 10/792,291

Art Unit: 1641

Tachikawa et al. teach a porous filter having immobilized antibodies, wherein the porous filter is nitrocellulose (par. 142), in order to provide a porous material that supports a ligand for a target analyte.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include as the porous filter layer in the bio-disc of Sheppard, Jr. et al., nitrocellulose as taught by Tachikawa et al., in order to provide a material on which a ligand for a target analyte is easily immobilized.

With respect to claim 17, Sheppard, Jr. et al. teach the substrate including encoded information associated therewith and encoded information being readable by a disc drive assembly to control the rotation of the bio-disc (col. 27, lines 24-31 and lines 42-46).

Regarding claim 18, Sheppard, Jr. et al. teach the bio-disc further comprising a reflective layer formed on a surface of the substrate (col. 10, line 64-col. 11, line 2; col. 16, line 43-col. 17, line 19).

With respect to claims 19 and 20, Sheppard, Jr. et al. teach a flow channel in fluid communication with the target zone and an input site in fluid communication with the flow channel (input means connected to detection chamber on surface platform, col. 5, lines 58-67; chambers on platform are in fluid communication with each other which indicates the presence of a flow channel, col. 12, lines 36-48; flow channel is capillary, col. 8, lines 26-40; Fig. 3A-3C) and an enzyme that when exposed to an enzyme substrate produces a signal (col. 6, lines 48-60) detectable by an incident beam of electromagnetic radiation (col. 22, lines 53-60).

Application/Control Number: 10/792,291

Art Unit: 1641

5. Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over Sheppard, Jr. et al. (US 6,143,247) in view of Tachikawa et al. (US 2002/0187510), as applied to claim 19, further in view of Christopherson et al. (US 2002/0019018).

Sheppard, Jr. et al. in view of Tachikawa et al. teach a plurality of capture antibodies immobilized on the bio disc, but fail to teach the plurality of capture antibodies having an affinity to a common surface marker on cells.

Christopherson et al. teach a target zone having a plurality of immobilized capture antibodies (par. 16, plurality of immunoglobulins immobilized in a discrete antibody spot, par. 142), wherein the capture antibodies in a single zone have an affinity to a common surface marker on cells (antibodies immobilized in a single discrete spot are directed to the same single epitope on an antigen, par. 142; antibodies may be directed to a surface marker on cells, par. 58), in order to detect the presence of cancer or a propensity to develop cancer.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include in the optical bio disc of Sheppard, Jr. et al. in view of Tachikawa et al., a plurality of capture antibodies in a single target zone having an affinity to common surface maker on cells as taught by Christopherson et al. because Sheppard, Jr. et al. is generic with respect to the antibodies that can be immobilized in the target zone and one would be motivated to use the appropriate antibodies for detection of the desired analyte.

6. Claims 55-66 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sheppard, Jr. et al. (US 6,143,247), as applied to claim 15, in view of Christopherson et al. (US 2002/0019018).

Sheppard, Jr. et al. teach a plurality of capture antibodies immobilized on the bio disc, wherein the plurality comprises populations of antibodies, each population having an affinity to a different analyte (col. 11, lines 9-12), but fail to teach the plurality of capture antibodies having an affinity to different cell surface markers.

Christopherson et al. teach a plurality of target zones each having a population of immobilized capture antibodies (par. 16, plurality of immunoglobulins immobilized in a discrete antibody spot, par. 142; plurality of spots each having a population "P" of capture antibodies, par. 123), wherein each antibody population has an affinity to a different cell surface marker (antibodies immobilized in different discrete spots are directed to the different cell surface antigens, par. 123 and 212), and with respect to claim 61, Christopherson et al. also teach that a plurality of capture antibodies may comprise a single population of antibodies that have an affinity to a single cell surface marker (plurality of antibodies in each discrete spot may have an affinity to the same epitope, which would be a single cell surface marker, par. 143 and 58), in order to detect the presence of cancer or a propensity to develop cancer.

Therefore it would have been obvious to one having ordinary skill in the art at the time the invention was made to include in the optical bio disc of Sheppard, Jr. et al., a plurality of populations of capture antibodies in target zones having affinities to different surface maker on cells as taught by Christopherson et al. because Sheppard, Jr. et al.

is generic with respect to the antibodies that can be immobilized in the target zone and one would be motivated to use the appropriate antibodies for detection of the desired analyte.

With respect to claims 56-58 and 61-64, Christopherson et al. teach that cells bound to antibodies from at least one population of antibodies (lymphoma cells bound to antibodies in discrete spots, Fig. 5 and par. 92; par. 221), wherein the cells are lymphocyte blood cells (par. 111 and 169), in order to detect the presence of cancer or a propensity to develop cancer.

It would have been obvious to one having ordinary skill in the art at the time the invention was made to include in the optical bio disc of Sheppard, Jr. et al., lymphocyte blood cells bound to capture antibodies as taught by Christopherson et al., in order to provide an assay device that detects cancer in blood samples.

Regarding claims 59, 60, 65 and 66, Sheppard, Jr. et al. teach all cells attached to beads (cells to be detected are mixed and attached to gold nanoparticles, which are beads, for labeling purposes, col. 15, lines 20-34).

#### Conclusion

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to MELANIE YU whose telephone number is (571)272-2933. The examiner can normally be reached on M-F 8:30-5.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mark Shibuya can be reached on (571) 272-0806. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Melanie Yu/ Primary Examiner, Art Unit 1641

#### Application/Control No. Applicant(s)/Patent Under Reexamination 10/792,291 COOMBS ET AL. Notice of References Cited Examiner Art Unit Page 1 of 1 **MELANIE YU** 1641 **U.S. PATENT DOCUMENTS** Document Number Date Name Classification Country Code-Number-Kind Code MM-YYYY US-2002/0019018 02-2002 Christopherson et al. 435/7.23 Α US-В US-С US-D US-Ε US-F US-US-Н US-US-US-Κ US-US-М FOREIGN PATENT DOCUMENTS Document Number Date Country Name Classification Country Code-Number-Kind Code MM-YYYY Ν 0 Ρ Q R S **NON-PATENT DOCUMENTS** Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) U W

A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).) Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

U.S. Patent and Trademark Office PTO-892 (Rev. 01-2001)

Х

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 10/792,291

Filing Date March 2, 2004

First Named Inventor James Coombs

Art Unit 1645

Examiner Not Yet Assigned

Attorney Docket No. NAGACO.074A

(Multiple sheets used when necessary)

SHEET 1 OF 3

		SHEET TOF 3		offiey bucket No. 14AGACO.	
U.S. PATENT DOCUMENTS					
xa in Fig.	GNEW NO.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevan Figures Appear
MY/	1	20020151043	10.17.2002	Gordon	
1	2	20020122364	09.05.2002	Worthington et al.	
	3	20030133840	07.17.2003	Coombs et al.	
	4	20030082568	05.01.2003	Phan et al.	
	5	20030104486	. 06.05.2003	Selvan	
	6	20030054376	03.20.2003	Mullis et al.	
	7	20030003464	01.02.2003	Phan et al.	
	8	20050047968	03.03.2005	Kido et al.	·
	9	20050019901	01.27.2005	Matveeva et al.	
	10	20040264323	12.30.2004	Worthington et al.	
	11	20030149599	08.07.2003	Goodall et al.	
	12	20050023765	02.03.2005	Coombs	
	13	20040241381	12.02.2004	Chen	
	14	20050003459	01.06.2005	Krutzik	
1 1	15	20050002827	01.06.2005	McIntyre et al.	
	16	20050032052	02.10.2005	Pal et al.	
	17	20040246252	12.09.2004	Morrow et al.	
	18	20030224457	12.04.2003	Hurt et al.	
	19	20030133840	07.17.2003	Coombs et al.	
	20	20030096324	05.22.2003	Matveev et al.	
	21	20040226348	11.18.2004	Bruce et al.	
	22	20030230383	12.18.2003	Sasaki	
	23	20030064872	04.03.2003	Worthington et al.	
	24	20030077627	04.24.2003	Worthington et al.	
	25	20020171838	11.21.2002	Pal et al.	
	26	20020151043	10.17.2002	Gordon	
1.	27	20020176342	11.28.2002	Worthington et al.	
$\mathbf{V}$	28	20020172980	11.21.2002	Phan et al.	
/MY/	29	20020168663	11.14.2002	Phan et al.	

	/Melanie Yu/ (01/08/2008)	
Examiner Signature	/Melanie Tu/ (01/00/2000)	I Date Considered
Limitor Digitatoro	,	

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

#### 10/792,291 Application No. INFORMATION DISCLOSURE Filing Date March 2, 2004 First Named Inventor **James Coombs** STATEMENT BY APPLICANT Art Unit 1645 Examiner Not Yet Assigned (Multiple sheets used when necessary) Attorney Docket No. NAGACO.074A SHEET 2 OF 3

	U.S. PATENT DOCUMENTS					
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
/MY/	30	20020163642	11.07.2002	Zoval et al.		
1	31	20020098528	07.25.2002	Gordon et al.		
	32	20020196435	12.26.2002	Cohen et al.		
	33	20020076354	06.20.2002	Cohen		
	34	20020145960	10.10.2002	Worthington et al.		
	35	20020168652	11.14.2002	Werner et al.		
	36	20020076805	06.20.2002	Virtanen		
	37	20020071362	06.13.2002	Worthington		
	38	20020097658	07.25.2002	Worthington et al.		
$\neg V$	39	20020071359	06.13.2002	Worthington		
/MY/	40	6,888,951	05.03.2005	Worthington		

FOREIGN PATENT DOCUMENTS							
/MY/	41	EP 0 311 492 A2	04-12-1989	Dominique Carrière	_		
\1/	42	2 WO 03/006956 A2	01-23-2003	Deborah Kim Glencross			
<b>V</b>	43	WO 02/44695 A1	06-06-2002	Pyapali, et al.			
/MY/	44	WO 00/05582	02-03-2000	Jorma Virtanen			

-		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	(hook magazina jaurnal carial cympacium catalog atc.) data paga(c) yaluma-issua nymbar(		T¹
/MY/	45	U.S. Patent Application 10/347,119, filed January 17, 2003 (Atty Docket No. NAGACO.029A). See file wrapper image.	
	46	U.S. Patent Application 10/351,604, filed January 23, 2003 (Atty Docket No. NAGACO.031A). See file wrapper image.	
	47	U.S. Patent Application 10/351,244, filed January 24, 2003 (Atty Docket No. NAGACO.033A). See file wrapper image.	
	48	U.S. Patent Application 10/370,272, filed February 19, 2003 (Atty Docket No. NAGACO.036A). See file wrapper image.	
V	49	U.S. Patent Application 09/421,870, filed October 26, 1999 (Atty Docket No. NAGACO.12CPCP). See file wrapper. image.	
/MY	50	U.S. Patent Application 09/643,106, filed August 21, 2000 (Atty Docket No. NAGACO.068A). See file image wrapper.	

Examiner Signature	/Melanie Yu/ (01/08/2008)	Date Considered	
	erence considered, whether or not citation is considered. Include copy of this form with		Draw line through citation if not

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

#### Application No. 10/792,291 INFORMATION DISCLOSURE Filing Date March 2, 2004 First Named Inventor James Coombs STATEMENT BY APPLICANT Art Unit 1645 Not Yet Assigned Examiner (Multiple sheets used when necessary) SHEET 3 OF 3 Attorney Docket No. NAGACO.074A

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>	
/MY/	51	International Search Report from PCT Application No PCT/IB2004/002780, mailed April 14, 2005		

1613655/eas 041505

Examiner Signature /Melanie Yu/ (01/08/2008) Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	Application No.	10/792,291
INFORMATION DISCLOSURE	Filing Date	March 2, 2004
ESTATEMENT BY APPLICANT	First Named Inventor	James Coombs
STATEMENT BY AFFEIGANT	Art Unit	1645
8		

SHEET 1 OF 2 Examiner Unknown

Attorney Docket No. NAGACO.074A

		<del>}</del>	U.S. PATENT DOCUMENTS					
, i i i i i			Document Number	U.S. PATENT	DOCUMENTS	Pages, Columns, Lines Where		
Exam Initia	als	Cite No.	Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Relevant Passages or Relevant Figures Appear		
/MY/		1	4,847,205	07-11-1989	Burtis et al.			
		2	5,631,166	05-20-1997	Charles R. Jewell			
		3	5,755,942	05-26-1998	Zanzucchi et al.			
		4	5,858,804	01-12-1999	Zanzucchi et al.			
		5	5,922,617	07-13-1999	Wang et al.			
		6	6,342,395 B1	01-29-2002	Hammock et al.			
		7	6,387,331 B1	05-14-2002	Ian W. Hunter			
		8	6,395,562 B1	05-28-2002	Hammock et al.			
		9	2002/0137218 A1	09-26-2002	Mian et al.			
		10	3,791,932	02-12-1974	Schuurs et al.			
		11	3,817,837	06-18-1974	Rubenstein et al.			
		12	3,850,752	11-26-1974	Schuurs et al.			
		13	4,104,029	08-01-1978	Maier, Jr.			
		14	4,233,402	11-11-1980	Maggio et al.			
		15	4,347,311	08-31-1982	Schmitz			
		16	4,472,509	09-18-1984	Gansow et al.			
		17	5,087,556	02-11-1992	Ertinghausen			
		18	5,120,662	06-09-1992	Chan et al.			
		19	5,1362,097	07-21-1992	Van Deusen et al.			
		20	5,585,069	12-17-1996	Zanzucchi et al.			
		21	5,892,577	04-06-1999	Gordon			
		22	6,143,247	11-07-2000	Sheppard, Jr. et al.			
	,	23	6,327,031 B1	12-04-2001	Gordon			
		24	2001/0001060 A1	05-10-2001	Kellogg et al.			
		25	2001/0055812 A1	12-27-2001	Mian et al.			
		26	3,654,090	04-04-1972	Shuurs et al.			
		27	3,939,350	02-17-1976	Kronick et al.			
		28	4,778,767	10-18-1988	Hummelen et al.			
/N	1Y/	29	5,262,302	11-16-1993	Thomas Russell			
<u>/N</u>	<u> </u>	29	5,262,302	11-16-1993	Thomas Russell			

Examiner Signature /Melanie Yu/ (01/08/2008) Date Considered

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T1 - Place a check mark in this area when an English language Translation is attached.

SHEET 2 OF 2

		Total Contraction
	Application No.	10/792,291
	Filing Date	March 2, 2004
	First Named Inventor	James Coombs
	Art Unit	1645
	Examiner	Unknown
Attorney Docket No.		NAGACO.074A
	, money booker no.	111010000

-	<u> </u>					
	Examiner Initials	Number - Kund Code (If Known)			Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
	/MY/	30	5,866,950	02-02-1999	Canavaggio et al.	

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>		
/MY/	31	WO 98/07019	02-19-1998	Gamera Bioscience Corp.				
	32	WO 98/38510	09-13-1998	Burstein et al.				
	33	WO 98/53311	11-26-1998	Gamera Bioscience Corp.				
	34	WO 02/06836 A2	01-24-2002	Karthe				
	35	GB 2 337 113 B	02-27-1997	Burstein				
	36	EP 0 504 432 A1	10-09-1991	Osawa et al.				
	37	EP 0 521 421 A2	01-07-1993	Takase et al.				
	38	EP 0 693 560 A2	01-24-1996	Becton Dickinson & Co.				
	39	WO 98/28623	07-02-1998	Sheppard et al.		-		
V	40	. WO 01/87487 A2	11-22-2001	Carvalho, et al.				
/MY/	41	EP 0 417 305 A1	03-06-1990	Idemitsu Petrochemical Co., Ltd.				

	NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ1		
/MY/	42	TIBBE, et al., Cell Analysis System Based on Immunomagnetic Cell Selection and Alignment Followed by Immunofluorescent Analysis Using Compact Disk Technologies, Cytometry, 2001, 43: 31-37			
/MY/	43	TIBBE, et al., Optical Tracking and Detection of Immunmagnetically selected and aligned cells, Nature Biotechnology, December 1999, Volume 7.			

1832579 072605

Examiner Signature

/Melanie Yu/ (01/08/2008)

Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.

PTO/SB/08 Equivalent

#### Application No. 10/792,291 INFORMATION DISCLOSURE Filing Date March 2, 2004 First Named Inventor James Coombs STATEMENT BY APPLICANT Art Unit 1641 Yu, Melanie J (Multiple sheets used when necessary) Examiner SHEET 1 OF 1 Attorney Docket No. NAGACO.074A

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	
/MY/	1	5,348,859 A	09-20-1994	Brunhouse et al.		
/MY/	2	2002/0072078 A1	06-13-2002	Tsai et al.		
/MY/	3	2002/0076804 A1	06-20-2002	Sheppard, JR et al.		

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
					1 ,	

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			

4719403 010708

Examiner Signature /Melanie Yu/ (01/17/2008) Date Considered

\*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.